Savient’s New Gout Treatment Hits Targets (SVNT)
Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is seeing its shares surging in pre-market trading. The company showed statistically significant positive results for the Puricase Phase III study in treatment-failure of gout ...Read Full Story »

